What does the evidence say about Phytosterols LDL Cholesterol Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Phytosterols LDL Cholesterol Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - In rats, phytosterol treatment altered gut microbial composition and the relative abundance of putative bile salt hydrolase (BSH)-producing taxa, accompanied by reduced ileal luminal BSH activity. [Xia J (2026); evidence level 4] - These changes coincided with bile acid remodeling, including increased concentrations of taurohyodeoxycholic acid (THDCA) in liver tissue and ileal contents. [Xia J (2026); evidence level 4] - Collectively, these findings suggest that dietary phytosterols may ameliorate dyslipidemia partly through modulation of the gut microbiota-bile acid-FXR axis, with microbiota-associated BSH-THDCA-FXR signaling representing one plausible contributing pathway. [Xia J (2026); evidence level 4] - Although dietary phytosterols have established lipid-lowering effects, their interactions with the gut-liver metabolic axis remain incompletely understood. [Xia J (2026); evidence level 4] - This review synthesizes mechanistic and clinical evidence on non-pharmacological strategies that modulate these pathways and contribute to ASCVD risk reduction. [Kovyanova TI (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.